Naive

Learn about the prevalence of pre-existing NPCs and efficacy/safety outcomes for participants with & without baseline NPCs in AMBER and EMERALD.

Baseline NPCs were found in 24% (88/362) of the D/C/F/TAF arm and 27% (99/363) of the control arm in the AMBER study, whereas 39% (294/763) of the D/C/F/TAF arm and 44% (163/378) of the control group were found to have NPCs in the EMERALD study. D/C/F/TAF led to high virological response rates at weeks 48 (range 86%-95%) and 96 (range 80%-91%), regardless of baseline NPCs. The primary purpose of this post hoc study was to compare individuals with and without baseline NPCs in terms of virological response (HIV-1 RNA 50 copies/mL) at week 48, using an intent-to-treat US Food and Drug Administration snapshot analysis.